NCT02808247 - Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 7, 2017

Primary Completion Date

November 3, 2020

Study Completion Date

April 14, 2021

Conditions

Sarcoma, Soft Tissue

Interventions

DRUG

Nintedanib

Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral

DRUG

Ifosfamide

Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2

Trial Locations (13)

1000

Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels

1066

The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis (301), Amsterdam

2300

Leiden University Medical Centre (310), Leiden

28040

Hospital Universitario San Carlos (366), Madrid

33076

Institut Bergonie, Bordeaux

Unknown

Cliniques Universitaires Saint-Luc (121), Brussels

U.Z. Leuven - Campus Gasthuisberg (147), Leuven

Centre Leon Berard (227), Lyon

Gustave Roussy (225), Villejuif

08661

Vilnius University Hospital Santariskiu Santaros Clinics Klinikos (9453), Vilnius

02 781

Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw

08916

Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia), Barcelona

SW3 6JJ

Royal Marsden Hospital - Chelsea, London (613), London